Physician profile
William C Thompson
NPI 1023073699
$13,693.82
in general payments reported to CMS, 2019-2025
60 companies · $2,058 in 2025
The $2,058 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,462 · 2020: $1,852 · 2021: $2,015 · 2022: $2,003 · 2023: $2,325 · 2024: $1,978 · 2025: $2,058.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,197 · Education: $164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,197.29 |
| Education | $163.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,667.14 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,348.85 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,036.03 | 2019-2025 | Qulipta, Ubrelvy, Linzess |
| Merck Sharp & Dohme LLC | $1,001.55 | 2019-2025 | Verquvo, Belsomra, Steglatro |
| Amgen INC. | $814.27 | 2019-2025 | Repatha, Prolia, Evenity |
| Pfizer INC. | $754.63 | 2019-2025 | |
| Lilly USA, LLC | $684.10 | 2019-2025 | Mounjaro, Jardiance, Trulicity |
| Glaxosmithkline, LLC. | $479.23 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $427.51 | 2019-2023 | Xarelto |
| Takeda Pharmaceuticals U.S.A., INC. | $412.98 | 2019-2025 | Trintellix, Eohilia |
| Novartis Pharmaceuticals Corporation | $367.46 | 2019-2025 | |
| Supernus Pharmaceuticals, INC. | $357.35 | 2019-2024 | Qelbree |
| Boehringer Ingelheim Pharmaceuticals, INC. | $278.58 | 2019-2024 | Synjardy, Jardiance |
| Allergan, INC. | $268.28 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $267.18 | 2022-2025 |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Thompson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.